Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alefacept + betamethasone dipropionate
- Development stage
- Discontinued
- Lead developer
- Biogen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intramuscular, Intravenous, Topical
01
Overview
Alefacept + betamethasone dipropionate is a combination therapy used for the treatment of moderate to severe plaque psoriasis. Alefacept is a recombinant fusion protein that binds CD2 and interferes with lymphocyte activation, while betamethasone dipropionate is a topical corticosteroid that helps relieve redness, itching, swelling, and other discomforts caused by psoriasis. The combination aims to provide enhanced therapeutic effect through dual mechanisms of action.
02
Targets
CD2 (T-cell Surface Antigen CD2)GR (Glucocorticoid receptor)ICAM3 (ICAM-3)
Beyond the preview
Go deeper on alefacept + betamethasone dipropionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alefacept + betamethasone dipropionate.